GeneDx (WGS) Q4 2025 Earnings Call Transcript
The Motley Fool
by newsfeedback@fool.com (Motley Fool Transcribing)February 23, 2026
AI-Generated Deep Dive Summary
GeneDx reported impressive financial results for Q4 2025, with total revenue reaching $121 million for the quarter and full-year revenue hitting $428 million. The company's exome and genome testing services saw a significant boost, growing 54% year over year, which translates to $104 million in quarterly revenue. This growth was driven by strong organic expansion, with organic exome and genome revenue increasing by 42% year over year, excluding a one-time payer recovery.
The company also highlighted its accelerating test volumes, delivering 27,761 exome and genome tests in Q4, up from 24% sequential growth in Q1 to 34% in Q4. The average reimbursement rate for these tests rose to $3,750 per test, a notable increase from $2,500 in 2023 and $3,000 in 2024. This upward trend contributed to improved gross margins, which reached 71% for both the quarter and full year, up significantly from 45% in 2023 and 65% in 2024.
GeneDx's adjusted net income for Q4 was $4.4 million, with a full-year figure of $4.8 million. The company has maintained strong market positioning, capturing 80% of exome/genome tests among specialists while targeting broader patient access. Its INFINITY dataset, featuring over 2.5 million rare genetic tests and extensive phenotypic data points, underscores its leadership in precision medicine. However, only 30% of eligible patients are being tested, indicating room for further growth.
Looking ahead, GeneDx provided guidance for fiscal 2026, projecting total revenue between $
Verticals
financeinvesting
Originally published on The Motley Fool on 2/23/2026